WuXi XDC Cayman Inc.（药明合联生物技术有限公司，股票代码：02268）于2026年4月8日发布截至2026年3月31日的股份变动月报表。报告期内，公司法定股本维持在10,000,000,000股，面值为每股0.00005美元，法定股本未发生变动。
报告显示，截至3月31日，公司已发行股份数量由上月底的1,257,992,705股增加至1,258,835,897股，新增843,192股，主要来源于若干首次公开发售前购股权计划的行使。本月无库藏股及回购注销记录，公司当月因行使期权获得的资金总额约人民币2,725,017.88元。
根据公告，截至3月底，公司已经满足了香港联交所对公众持股量的相关要求。公司进一步确认所有新增发及股份转让均符合香港联交所《上市规则》及相关法律要求。
公告由执行董事、首席财务官兼公司秘书席晓捷签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.